Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304449 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP3A4SLC6A4KLK5TAAR1 | |
| SCHEMBL13613938 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP3A4SLC6A4KLK5TAAR1 | |
| SCHEMBL25355213 | 0.85 | ACE (0.55) | SMN1; SMN2CYP3A4SLC6A4TAAR1CYP2D6 | |
| SCHEMBL9958960 | 0.85 | ACE (0.55) | SMN1; SMN2CYP3A4SLC6A4TAAR1CYP2D6 | |
| SCHEMBL9958965 | 0.85 | ACE (0.55) | SMN1; SMN2CYP3A4SLC6A4TAAR1CYP2D6 | |
| SCHEMBL7630814 | 0.83 | PSEN1 (0.51) | KLK5ALDH1A1 | |
| SCHEMBL7630812 | 0.83 | PSEN1 (0.51) | KLK5ALDH1A1 | |
| SCHEMBL25132143 | 0.83 | TAAR1 (0.58) | SMN1; SMN2CYP3A4SLC6A4TAAR1CYP2D6 | |
| SCHEMBL25132031 | 0.83 | TAAR1 (0.58) | SMN1; SMN2CYP3A4SLC6A4TAAR1CYP2D6 | |
| SCHEMBL31327540 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP3A4SLC6A4TAAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673772-B2 | INHIBITING THE ENZYMATIC ACTIVITY OF HIV PROTEASE | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-01-06 | — | — | US | disclosed |
| US-20020049165-A1 | Novel dipeptide compounds and their use as medicines | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| EP-1157997-A1 | NOVEL DIPEPTIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN ENERGY CORPORATION (JP) | 2001-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049165-A1 | Novel dipeptide compounds and their use as medicines | DNPEP, PEPD, ANPEP | SMN1; SMN2 4212/4885CYP3A4 781/4885SLC6A4 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.